Circulation. Arrhythmia and electrophysiology
-
Circ Arrhythm Electrophysiol · May 2021
The Association of Structural Inequities and Race With Out-of-Hospital Sudden Death During the COVID-19 Pandemic.
[Figure: see text].
-
Circ Arrhythm Electrophysiol · Mar 2021
Multicenter StudyWorldwide Survey of COVID-19-Associated Arrhythmias.
[Figure: see text].
-
Circ Arrhythm Electrophysiol · Jan 2021
Randomized Controlled Trial Multicenter StudyProspective Randomized Evaluation of High Power During CLOSE-Guided Pulmonary Vein Isolation: The POWER-AF Study.
CLOSE-guided atrial fibrillation (AF) ablation is based on contiguous (intertag distance ≤6 mm), optimized (Ablation Index >550 anteriorly and >400 posteriorly) point-by-point radiofrequency lesions. The optimal radiofrequency power remains unknown. ⋯ This randomized controlled study shows that a 45 W radiofrequency power CLOSE protocol in patients with paroxysmal AF significantly increases the global procedural efficiency with similar midterm efficacy. However, our study showed a narrower safety margin and a limited increased efficiency at the posterior wall using high power. This advocates against the use of high power in the region neighboring the esophagus.
-
Circ Arrhythm Electrophysiol · Dec 2020
Artificial Intelligence-Electrocardiography to Predict Incident Atrial Fibrillation: A Population-Based Study.
An artificial intelligence (AI) algorithm applied to electrocardiography during sinus rhythm has recently been shown to detect concurrent episodic atrial fibrillation (AF). We sought to characterize the value of AI-enabled electrocardiography (AI-ECG) as a predictor of future AF and assess its performance compared with the CHARGE-AF score (Cohorts for Aging and Research in Genomic Epidemiology-AF) in a population-based sample. ⋯ In the present study, both the AI-ECG AF model output and CHARGE-AF score independently predicted incident AF. The AI-ECG may offer a means to assess risk with a single test and without requiring manual or automated clinical data abstraction.
-
Circ Arrhythm Electrophysiol · Nov 2020
Multicenter StudySafely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
The severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) has resulted in a global pandemic. Hydroxychloroquine±azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of evidence regarding efficacy. The incidence of torsade de pointes remains unknown. Widespread use of these medications forced overwhelmed health care systems to search for ways to effectively monitor these patients while simultaneously trying to minimize health care provider exposure and use of personal protective equipment. ⋯ The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy.